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Background. Teratoma withmalignanttransformation(TMT) is rare and mostcommonlyencountered in adult patient with germ
cell tumor (GCT). Method. We report a rare case of testicular teratoma with metastatic TMT/embryonal rhabdomyosarcoma
(ERMS). A 44-year-old man underwent right orchiectomy which revealed a malignant teratoma, he subsequently had right
pneumonectomywithtwopulmonarymassescontainingahigh-gradeembryonalrhabdomyosarcoma.Thepatientdeveloped liver
metastasis three months after initial diagnosis. He was treated with a chemotherapy regimen with vincristine, dactinomycin, and
cyclophosphamide(VAC) alternating with vincristine and irinotecan (VI) with complete resolution of his liver lesion.The tumors
were examined with a battery of cytogenetic, immunohistochemical, and molecular assays. Results. The malignant cells were
immunohistochemically positive for desmin, myogenin, and MyoD1. Molecular cytogenetics of embryonal rhabdomyosarcoma
tissue revealed the presence of i(12p). The tumor expressed high level of TOPO2A, TOPO1, MRP1, MGMT, BCRP, ERCC1,
RRM1, and TS. Conclusion. The activity of topoisomerase inhibitors and the potential usefulness of topoisomerase expression
as biomarkers should be further tested in aprospective study.
1.Introduction
Teratoma with malignant transformation (TMT) is germ
cell tumor (GCT) which underwent malignant transfor-
mation of a somatic teratomatous component to histology
that is identical to a somatic malignancy (e.g., carcinoma
or sarcoma) [1–8]. TMTs are rare and most commonly
encountered in adult patients with GCT. The most frequent
malignant components associated with testicular GCT are
sarcoma [1, 4]. TMTs are usually metastatic at presentation,
have a high recurrence rate, and are more aggressive than
teratomas without malignant transformation [5–8]. The
prognosis is especially poor for mediastinal TMTs and for
those with neural or rhabdomyosarcomatous diﬀerentiation
[1, 2, 7]. Surgical resection is the mainstay of therapy for
localizeddisease,becauseTMTsareconsideredtoberesistant
to radiation and systemic chemotherapy [8–11]. Eﬀective
therapeutic strategies targeted to TMT are needed. A case of
TMT successfully treated according to a combined modality
is presented here along with a description of immunohisto-
chemistry, molecular cytogenetics assays results.
2.Case Report
The patient is a 44-year-old Caucasian male who presented
with one-month history of weight loss, cough, pleuritic
chest pain and dyspnea. Computed tomography of the
chest revealed two right lung masses that measured 6.8 and
10.5cm (Figure 1). Fine needle aspiration biopsy showed
high-grade sarcomatoid malignancy which consistent with
embryonal rhabdomyosarcoma. Upon further investigation
a right testicular mass was noted. However α-fetoprotein, β-
human chorionic gonadotropin, carcinoembryonic antigen
(CEA), and lactate dehydrogenase assays were normal.
A right orchiectomy revealed a malignant teratoma. The
patient was subsequently transferred to our hospital for2 Sarcoma
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Figure 1: Chestcomputed tomography(CT) showed large right lungmasses;the right upper lobe massmeasured 6.8cm,a large right lower
lobe measured 10.5cm.
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Figure 2: 18F-FDG coincidence scintigraphy showed increased FDG uptake in right lung masses.
chest pain and hemoptysis. A bronchoscopy was performed
which did not show any active bleeding, a suspicious en-
dobronchial lesion was biopsied that showed no evidence
of malignancy. PET scan showed increase uptake in both
pulmonary lesions (Figure 2). The patient subsequently had
right pneumonectomy.
The patient developed a 4cm liver metastasis two
monthsafterpneumonectomy.The patientwassubsequently
treated according to the arm II of ARST0531 [12]p r o t o c o l
(A Randomized Study of Vincristine, Dactinomycin, and
Cyclophosphamide (VAC) versus VAC Alternating with Vin-
cristine and Irinotecan (VI) for Patients with Intermediate-
Risk Rhabdomyosarcoma; VAC alternating with vincristine
and irinotecan hydrochloride: vincristine IV over 1 minute
on day 1 of weeks 1–13, 16, 17, 19, 20, 22–26, 28, 31–34, 37,
38, and 40; dactinomycin IV over 1–5 minutes on day 1 of
weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1
houronday1ofweeks1,10,13,22,28,34,and40;irinotecan
hydrochloride IV over 1 hour on days 1–5 of weeks 4, 7, 16,
19, 25, 31, and 37). He had a complete response of his liver
lesion and remains disease-free at 16 months of follow-up
after initial diagnosis.
3.Pathologic and CytogeneticsFindings
Pathologic examination of the right pneumonectomy spec-
imen revealed two masses measuring 10.1 × 9.8 × 7.4cm
and 10.9 × 9.4 × 8.1cm, grossly abutting the visceral pleura
with a thickened ﬁbrotic capsule. Both of the tumor masses
were ﬁrmrubberywithhomogenoustan-white ﬁbrousﬂeshySarcoma 3
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Figure 3: Histopathological ﬁndings of the pulmonary tumor. H & E stained section of pulmonary tumor demonstrating rhabdomyosar-
coma showing rhabdoid cells (a) and chondrosarcoma with hyaline cartilage diﬀerentiation (b). Rhabdomyoblasts are positive for desmin
(c) and myogenin (d).
cut surfaces. The tumor obliterated most of the normal lung
parenchyma with only scattered residual entrapped alveoli.
Microscopically, the tumor was composed predomi-
nantly of pleomorphic spindle to round cells with scant
cytoplasm and round-to-irregular hyperchromatic nuclei
(Figure 3(a)). Rhabdoid cells with abundant eosinophilic
cytoplasmand eccentricnuclei,were abundant(Figure3(a)).
Rare scattered cells with more terminal diﬀerentiation (strap
cell) were also noted. Tumor also demonstrated a focal area
of chondrosarcomatous diﬀerentiation consisting of round
tospindlecellswithpericellularclearing;fociofhyalinecarti-
lage were also noted (Figure 3(b)). The tumor demonstrated
a brisk mitotic activity and multifocal necrosis. Immun-
ohistochemistry showed that the tumor cells were positive
for desmin (Figure 3(c)), myogenin (Figure 3(d)), MyoD1,
and CD99, and negative for pancytokeratin, CAM5.2, actin,
and OSCAR (not shown). The ﬁnal diagnosis was metastatic
embryonal rhabdomyosarcoma with a focal area of chon-
drosarcoma. Both tumor’s masses show the same histology.
No GCT was identiﬁed. Surgical margins were negative.
Multiple lymph nodes were harvested without evidence of
malignant involvement.
Pathologic examination of the testicular mass showed a
malignant germ cell tumor composed of teratoma. There
was no evidence of immature or somatic type malignant
components upon extensive sampling. Fluorescence in situ
hybridization (FISH) studies were performed on paraﬃn
sections from lung mass utilizing Homebrew 12p13.2 DNA
probe with CEP 12 at the University of Nebraska Medical
Center genetics laboratory. Molecular cytogenetic analysis
revealed a normal male 46, XY karyotype with presence of
i(12p).
4.TumorProﬁlingby
Immunohistochemistry Analysis
In ordertoidentify potentialtargetand biomarkersand ther-
apies associated with clinical beneﬁt, further immunohisto-
chemistry andmolecularstudieswereperformed. Asdemon-
strated by Figure 4, Immunohistochemistry study showed
high expression of the following proteins: Topoisomerase-
II alpha (Topo IIa; 2+, 30%), Topoisomerase I (Topo I; 2+,
10%). In addition, Multidrug resistance-related protein-1
(MRP1) (1+, 60%), O6-methylguanine-DNA methyltrans-
ferase, (MGMT; 1+, 90%), breast cancer resistance protein4 Sarcoma
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Figure 4: Immunohistochemistry ﬁndings of the pulmonary tumor. (a) Rhabdomyoblasts with Topo 2a, (b) Topo I.
(BCRP; 2+, 90%), excision repair cross-complementation
group 1 (ERCC1; 1+, 10%), ribonucleoside-diphosphate
reductase large subunit (RRM1; 2+, 80%), and thymidylate
synthase (TS; 2+, 50%).
5.Discussion
Somatic-type malignancies develop in 3% to 6% of GCT
with teratomatous diﬀerentiation [1, 4]. It was postulated
that they develop from either malignant transformation
(MT) of pre-existing teratomatous elements or by diﬀerenti-
ation of totipotential germ cells with concomitant MT. The
most frequent somatic malignancies associated with GCT
are sarcomas, rhabdomyosarcoma being the most common
subtype [1, 2]. Upto 80% ofpatients with TMT present with
metastases have a high recurrence rate and poor prognosis
whereas others present with unresectable disease [5].
A notable feature of current case is the fact that no
sarcomatous componentwas identiﬁed in the testicular mass
and no germ cell element was identiﬁed in the resected
pulmonary tumor. Although extensive histopathologic eval-
uation was undertaken,sampling error cannot be completely
excluded. The presences of two diﬀerent types of sarco-
mas (i.e., rhabdomyosarcoma and chondrosarcoma) in the
same metastasis favor a GCT origin. The GCT origin of
rhabdomyosarcoma in this case is also strongly supported by
the presence of i(12p). Chromosomal abnormalities in these
TMTs include i(12p), reﬂecting germ cell tumor clonality,
as well as chromosomal abnormalities associated with the
transformed histology. Only a few cytogenetic studies have
been performed on transformed tumors [13]. Motzer et al.
reported i(12p) in 10 of 12 transformed tumors studied
including adenocarcinoma, peripheral primitive neuroecto-
dermal tumor, and rhabdomyosarcoma [1].
The treatment of TMTs remains a challenge. TMTs have
traditionally beenthought to be unresponsive to chemother-
apy, including cisplatin-containing chemotherapy regimens
[10]. Patients who had complete resection of TMTs had sig-
nificantly better overall survival, and the prognosis for pa-
tients with metastatic disease was very poor [3]. Recent
reports indicate that chemotherapy directed against trans-
formed component may achieve better results [11]. There
have been only a few reports of successful treatment of
metastaticTMTswithchemotherapywithlong-termsurvival
to doxorubicin-based chemotherapy [10, 11].
Our ﬁnding of overexpression of several drug-resistant
genes is in line with the clinical observations of lack of re-
sponse to chemotherapy in these tumors. High expression of
MRP1 has been associated with lackof response to etoposide
andvincristine [14].Highexpression ofBCRPhas beenasso-
ciated with shorter progression-free (PFS) and overall sur-
vival (OS), when treated with platinum-based combination
chemotherapy [15, 16]. In addition, genes encode enzyme
that catalyzes the biosynthesis of nucleic acid (RRM1), and
gene encodes macromolecular target of a cytotoxic drug
(MGMT, TS) also over expressed. High expression of RRM1
expression was associated with lack of response to gemcita-
bine and poor outcome [17]. High expression of MGMT has
been linked with resistance to temozolomide-based therapy
[18]. High TS has been associated with lack of response to
ﬂuoropyrimidine [19].
T h eo u t c o m ef o rp a t i e n t sw i t hm e t a s t a t i cR M Sh a sr e -
mained approximately 30% survival for several decades. It
has long been recognized that interpatient variability in
response to chemotherapy is associated with diﬀerent out-
comes. The complete clinicalresponse with irinotecan-based
regimen in this case is interesting. The overexpression of
TopoIIa,TopoIintumorsuggestedtheyareattractivetargets
for novel therapy. Topo I and IIa are enzymes that alter
the supercoiling of double-stranded DNA. They act by tran-
siently cutting one or both strands of the DNA. Topo I cuts
one strand whereas topoisomerase II cutsboth strands of the
DNA to relax the coil and extend the DNA molecule [20].
High expression of Topo I has been associated with response
to ﬁrst-line chemotherapy containing irinotecan, a Topo I
inhibitor while overexpression of Topo IIa conferred higher
probability of response to doxorubicin, a DNA intercalating
agent [21, 22].
Theadventofthehumangenomesequencingprojectand
thedevelopmentofhigh-throughput technologies, includingSarcoma 5
microarrays,haveallowedoncologiststoexplorethepossibil-
ity of using gene expression proﬁles to predict chemotherapy
drug sensitivity or resistance before treatment, and thereby
select the best possible therapies while decreasing the risk
of toxicities for the patients. In order to achieve this goal,
an international virtual sample bank of this rare tumor is
necessary. The Sarcoma Foundation of American Patient
Registry and ongoing international eﬀorts to evaluate high-
dose chemotherapy in the salvage setting (TIGER protocol)
may provide a good opportunity to collect such rare cases.
In conclusion, we report a rare case of malignant testic-
ular teratoma with metastatic TMT/ERMS. Our ﬁndings of
overexpression of several drug-resistant genes is consistent
with the previous clinical observations of poor chemother-
apy response in these tumors. The usefulness of biomarkers
for chemotherapy selection should be further tested in a
future study.
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